Preparation and Evaluation of Mixture of Eudragit and Ethylcellulose Microparticles Loaded with Ranolazine for Controlled Release by Gowda, DV et al.
Journal of Young Pharmacists Vol 3 / No 3  189
Pharmaceutics
INTRODUCTION
In recent years, considerable attention has been focused on 
the development of novel drug delivery system (NDDS). 
The reason for this paradigm shift is the low development 
cost and time required for introducing an NDDS, as 
compared to a new chemical entity. In the form of NDDS, an 
existing drug molecule can get a new life, thereby increasing 
its market value, competitiveness, and product and product 
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ABSTRACT
To minimize the unwanted toxic effects of anti-anginal ranolazine by kinetic control of drug release, it was 
entrapped into gastro-resistant, biodegradable eudragit (EU) and ethyl cellulose (EC) binary blend using 
phase separation method. Ten formulations were prepared using different polymer blend ratios and solvent. 
The prepared microparticles were characterized for micromeritic properties, polymer drug compatibility by 
Fourier Transform Infrared Spectroscopy (FT-IR) and Differential Scannibg Calorimetry (DSC), and surface 
morphology by Scanning Electron Micrography (SEM). The yield of microparticles was up to 90% and more 
than 98% of the isolated microparticles are having volume mean diameter of 285 µm. The obtained angle 
of repose, percentage Carr’s index and tapped density values were within the limits indicating good flow 
properties. The surface morphology revealed that particles were free-flowing, spherical, with minute pores and 
invert dents on the surface. The prepared microparticles were evaluated for percentage yield, encapsulation 
efficiency and in vitro release studies. FT-IR and DSC studies showed no chemical interaction between the 
drug and used polymers The in vitro drug release studies were carried out using pH 1.2 acid buffer and pH 7.4 
phosphate buffer. EU acts as an excellent pH-dependent binder and helps to release the drug in the intestine. 
The drug release kinetics followed different transport mechanisms. Increasing the weight fractions of EU and 
decreased EC helps to control the drug release from the particles. From the differential (f1) and similarity 
factor (f2), Formulation F5 was the formulation most similar to the commercially available oral formulation as 
reference standard. The drug release performance was greatly affected by the materials used in microparticle 
preparations, which allow absorption in the intestinal tract.
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patent life. Among the various NDDS available in the market, 
the oral controlled release systems hold a major portion 
of the market because of their ease of administration and 
better patient compliance.[1] In the conventional oral drug 
delivery, which is a convenient method to achieve both local 
and systemic effects, there is a little or no control over drug 
release from dosage forms. An effective concentration at the 
target site can be achieved by intermittent administration of 
a grossly excessive dose, which results in constantly changing, 
unpredictable, and often sub or supra therapeutic plasma 
concentration, leading to marked side-effects.[2]
The goal of any drug delivery is to provide a therapeutic 
amount of drug to the proper site in the body in order to 
promptly achieve and thereby to maintain the desired drug 
concentration during treatment. The idealized objective 
can be achieved by a controlled release mechanism of a 
poorly water-soluble drug, which easily mixes with the 
mixture of polymeric matrix and shows good absorption 
rate. The mixture of the polymeric matrix materials used 
in the present study has good pharmaceutical properties. 
However, the reported methods are not suitable for 
all drugs. Among the reported conventional methods 
different strategies have been developed. In recent years 
many research have already been carried out in order 
to design different types of matrix-type microparticles 
loaded with hydrophilic and lipophilic drugs using toxic 
solvents. The use of such solvents during formulation is 
of environmental concern and challenges human safety. 
To overcome this problem, in the present study, water 
has been used to prepare matrix-type microparticles by 
phase separation method. Moreover, these matrix-type 
microparticles offer double benefits. Firstly, particle size 
is reduced to a minimum level and secondly, the presence 
of insoluble polymer(s) in the matrix would modify the 
drug release rate by changing the matrix permeability.
Ranolazine (RNZ), a novel anti-anginal agent belonging 
to the group of piperizine acetamide has been widely 
used in the treatment of cardiovascular diseases, including 
arrhythmias, variant and exercise-induced angina, and 
myocardial infarction.[3]
It has been reported that RNZ improves the myocardial 
oxygen balance between the supply and demand of the 
ischemic heart, by increase in the coronary blood flow. 
However, to achieve and maintain the drug concentrations 
within the therapeutic range, it is often obligatory to 
take the dosage forms several times a day. The most 
frequently reported side-effects (unwanted effects) 
occurring in more than 2% of people taking RNZ include 
the following: Dizziness, headache, constipation, nausea.
Oral controlled multiparticulate dosage forms such as 
microparticles are becoming more popular than the 
single-unit dosage form. Microparticles showed more 
reproducible drug absorption and reduced risk of local 
irritation at the gastrointestinal tract.
Eudragit (EU) and ethyl cellulose (EC) have been used as 
drug carriers to achieve controlled drug delivery for the past 
few decades. These polymers have gained a lot of interest 
owing to their versatile properties.
The present study aims to prepare RNZ microparticles 
using the phase separation method and to characterize 
the microparticles for micromeritic properties, drug 
loading, Fourier Transform-Infrared Spectroscopy   
(FT-IR), differential scanning calorimetry (DSC) and in vitro 
release studies.
MATERIALS AND METHODS
RNZ was provided as a gift sample by Zydus Cadila 
Healthcare Ltd., Ahmedabad. EU RLPO was provided 
as a gift sample from Degussa India Pvt. Ltd., Mumbai. 
ECL was purchased from Loba Chemie Pvt. Ltd., 
Mumbai. All other reagents used were of analytical 
grade.
Preparation of microparticles
Drug-loaded microparticles were prepared by phase 
separation method.[4] Weighed amounts of RNZ were 
dissolved in 70 ml of acetone and this solution was added 
to EU and ECL polymer blend at different ratios. Under 
constant stirring at 3000 rpm, 30 ml of non-solvent, 
purified water was added drop-wise to the drug and the 
polymer solution (1 ml/min). In the course of the water 
addition, the drug and the polymer were co-precipitated 
out to form microparticles. The resultant microparticles 
were separated by vacuum filtration and  dried at room 
temperature for 72 h. The dried microparticles were stored 
in a desiccator at room temperature. Formulation chart is 
presented in Tables 1 and 2.
Characterization of microparticles
Particle size analysis
The particle size was measured using a Malvern 
MASTERSIZER 2000 version 5.1 (Malvern, UK.) 
The samples of RNZ microparticles were dispersed in 
methanol in a ratio of 1:20 and measured at a temperature 
of 37°C.[5,6]Journal of Young Pharmacists Vol 3 / No 3  191
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Angle of  repose
Fixed-funnel method was employed for determining 
angle of repose. The angle of repose (q) for samples was 
calculated using the formula,
Angle of repose (q) = tan−1 (h/r)  (1)
Where ‘h’ is height of heap and ‘r’ is radius of the heap.
Compressibility
Tapped density was determined by placing a graduated 
cylinder containing a known mass of powder on a 
mechanical tapper apparatus (Electro lab tap density 
tester). Carr’s index was calculated using the formula   
Carr’s index = (tapped density – bulk density) / tapped 
density
Fourier transform infrared spectroscopy
Drug polymer interactions were studied by Fourier Transform-
Infrared Spectroscopy (FT-IR) spectrophotometer 
(Shimadzu, 8033, USA) by KBr pellet method.[7] The IR 
spectrum of the pellet from 400 – 4000 cm−1 was recorded.
Differential scanning calorimetry
All dynamic differential scanning calorimetry (DSC) 
studies were carried out on dupont thermal analyzer with 
2010 DSC module.[8] The instrument was calibrated using 
high-purity indium metal as standard. The dynamic scans 
were taken in nitrogen atmosphere at the heating rate of 
10ºC/min.
Scanning electron microscopy
Scanning electron microscopy (SEM) photographs were 
taken for the prepared microparticles with a scanning 
electron microscope, Joel-LV-5600, USA, at the required 
magnification in room temperature. The photographs were 
observed for morphological characteristics. Photographs 
were taken at the magnifications of 400¥, 1500¥ and 
3000¥.[9,10]
Percentage yield
The yield was determined by weighing the microparticles 
and then finding out the percentage yield with respect to 
the weight of the input materials, i.e. weight of drug and 
polymer mixtures used. The formula for calculation of 
percentage yield is as follows;
%
.
.
 yield 
wt  of drug polymer mixture
wt  of microparticles
=¥ 1 100 (2)
Drug loading and encapsulation efficiency
One hundred mg of RNZ microparticles were weighed 
and transferred to a 100-ml volumetric flask containing 
pH 7.4 phosphate buffer. From this, 1 ml of solution 
was transferred to a 10-ml volumetric flask and diluted. 
Further 1 ml of this solution was diluted to 10 ml and 
absorbance was measured at 270 nm.[11] The drug content 
was calculated by using the formula:
Amount of drug
Conc  from standard graph   dilution factor
=
¥ .
1 1000
 (3)
Percentage encapsulation efficiency was found out by 
calculating the amount of drug present in 100 mg of 
microparticles.
In vitro drug release studies
The in vitro release of drug from the microparticles was 
carried out in basket-type dissolution tester USP XXIII, 
TDT-08L, with auto sampler containing 900 ml of 
dissolution media ( pH 1.2 buffer for the first 2 h and in   
pH 7.4 phosphate buffer for the next 10 h. The volume 
of the dissolution media was maintained at 900 ml with 
constant stirring (100 rpm) and temperature of bath was 
maintained at 37 ± 0.5°C. Aliquots (10 ml) of dissolution 
media were sampled at specified time intervals and 
replaced with fresh media immediately after sampling. 
Samples were analyzed for drug content by Ultraviolet 
UV visible spectroscopy (Shimadzu UV 1601).The release 
data obtained were fitted into various mathematical 
models.
Dissolution studies were carried out for all the batches of 
the prepared formulations (10 batches) and compared with 
the commercial formulation Ranexa SR 200.
Table 1: Formulation chart of prepared RNZ-loaded 
microparticles from F1 to F5
Ingredients F1 F2 F3 F4 F5
RNZ (mg) 300 300 300 300 300
EU RLPO (mg) 150 100 200 75 225
EC (mg) 150 200 100 225 75
Acetone (ml) 70 70 70 70 70
Purified water (ml) 30 30 30 30 30
Table 2: Formulation chart of prepared RNZ-loaded 
microparticles from F6 to F10
Ingredients F6 F7 F8 F9 F10
RNZ (mg) 300 300 300 300 300
EU RLPO (mg) 150 100 200 75 225
EC (mg) 150 200 100 225 75
DMF (ml) 30 30 30 30 30
Acetone (ml) 40 40 40 40 40
Purified water (ml) 30 30 30 30 30192   Journal of Young Pharmacists Vol 3 / No 3
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Drug release kinetics
In order to understand the mechanism and kinetics of drug 
release, the drug release data of the in vitro dissolution study 
was analyzed with various kinetic equations. Coefficient 
of correlation (r) values were calculated for the linear 
curves obtained by the regression analysis of the above 
plots.[12] A differential factor (f1) and similarity factor (f2) 
were calculated from the dissolution data according to the 
following equations:
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where, f1 – differential factor, f2 – similarity factor, n – 
number of time point, Rt – dissolution value of the reference 
at time, ‘t’ and Tt – dissolution value of test formulation 
at time ‘t’. Differential factor, f1 was calculated by the 
percentage difference between the two curves at each time 
point and measured the relative error between the two 
curves. The acceptable range for differential factor f1 is 
0-15. The similarity factor f2 was the logarithmic reciprocal 
square root transformation of the sum-squared error and 
is a measure of the similarity in the percentage dissolution 
between the reference and test products. The similarity value 
(f2) obtained from dissolution profile of the reference and 
test products should be in the range 50-100.
RESULTS AND DISCUSSION
Ten formulations were prepared using different polymer 
blend ratios. The drug: Polymer ratio used in all the 
formulations was 1:1. Various formulation and process 
variables that could affect the preparation and properties 
of the microparticles were identified and optimized to get 
small, discrete, uniform, smooth-surfaced, and spherical 
microparticles. The formulation variables included 
concentration of the polymer blend and the solvent used. 
The process variables included the stirring speed and time.
In the first five formulations (F1-F5), the drug was dissolved 
in acetone and in the next five formulations (F6-F10), the drug 
was dispersed in dimethyl formamaide (DMF) and acetone.
An important factor that influences the size distribution 
of microparticles is the optimum stirring speed and time. 
A stirring speed of 3000 rpm and 40 min stirring time 
was used to obtain reproducible microparticles. It was 
observed that with the increase in the stirring speed from 
3000-3500 rpm, there was a decrease in the average size of 
the microparticles and recovery yield of the microparticles. 
It was due to the loss of microparticles that occurred 
during successive filtration. When the stirring speed was 
lower than 3000 rpm, larger microparticles were formed. 
The resultant microparticles were composed of irregular 
masses, which were not possible to distinguish as discrete 
individual microparticles are shown  in the Figure 1.
When the stirring time was lower than 40 min, it was observed 
that some amount of the dissolved mass adhered to the inner 
sides of the beaker, resulting in lower percentage yield. The 
effect of stirring time on percentage yield is presented in 
Table 3. As we increase the stirring time there will be more 
stirring time available which causes particle size to decrease 
to the extent that particle loss occurs during filtration process 
which reduces percent yield of microparticles.
From the above results it was observed that an optimum 
time of 40 min produces a good yield of microparticles. 
Formulation F5 showed better yield when compared to the 
other formulations, and results are presented in Table 4.
Figure 1: SEM photograph of RNZ microparticles obtained at low 
stirring speed
Table 3: Effect of stirring time on percentage yield of 
RNZ-loaded microparticles
Time in minutes % yield
10 45.11
20 60.40
30 79.22
40 90.87
50 88.08
60 73.42
70 62.72Journal of Young Pharmacists Vol 3 / No 3  193
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Repeated batches of microparticles were prepared at an 
optimized rate (stirring speed and stirring time) which 
shows reproducibility of microparticles.
The flow property of the prepared RNZ microparticles 
was studied by determining the angle of repose (θ) and % 
compressibility index (CI). The obtained data along with 
related parameters are presented in Table 5. The values of 
θ ranged from 26.24 to 29.12 and the Carr index was found 
to be between 11.22–15.01%. These results indicated that 
the prepared microparticles exhibited good flow properties.
The values of tapped density ranged between   
0.210–0.301 g/cm3. The density difference between 
the formulations was negligible and the density values 
of formulations were well within the acceptable limits, 
indicating that the prepared microparticles were non-
aggregated.
The average particle size/volume mean diameter (D [4, 3]) 
and volume median diameters (D [v, 0.5]), (D [v, 0.9]) of 
the microparticle formulation of RNZ (F5) are given in 
Table 6 and the particle size graphs are given in Figure 2. 
D [4, 3] is the volume mean diameter of the microspheres 
whose size is being determined. D [v, 0.50] is the median 
diameter and it is the value of the particle size that divides 
the population into two equal halves i.e. there is 50% of 
distribution above this and 50% below this value. D [v, 0.90] 
is the median diameter and it is the cutoff value for the 
distribution, which means 90% of the distribution (particle 
size value) is below this value.
RNZ pure drug and the optimized formulation were 
subjected for FT-IR spectroscopic analysis for compatibility 
studies and to ascertain whether there is any interaction 
between the drug and the polymers used [Figure 3]. From 
the data it is clear that similar characteristic peaks with 
minor differences were observed in drug and formulation. 
Hence it appears that there is no chemical interaction 
between the drug and the polymer. It can be concluded that 
the characteristics bands of pure drugs were not affected 
after successful loading. In order to investigate the possible 
interaction between the drug and the polymers, DSC studies 
were carried out. RNZ exhibits a sharp endothermic peak 
at 124.28 corresponding to its melting point and a similar 
condition was also observed in the formulation confirming 
the stability of the drug in the formulation [Figure 4].
Table 4: Percentage yield for RNZ-loaded 
microparticles
Formulation  % Yield ± SD* 
F1  86.22 ± 1.44 
F2  87.70 ± 1.56 
F3  86.46 ± 1.24 
F4  87.42 ± 1.54 
F5  91.44 ± 1.36 
F6  85.12 ± 1.72 
F7  86.32 ± 1.12 
F8  87.63 ± 1.32 
F9  84.43 ± 1.26 
F10  88.66 ± 1.46 
*Standard deviation, n = 3
Table 5: Micromeritic properties of RNZ-loaded 
microparticles
Formulation θº 
Mean ± SD*
CI%  
mean ± SD*
Tapped density (g/cm3) 
mean ± SD*
F1 29.10 ± 0.41 14.25 ± 0.66 0.301 ± 0.05
F2 28.75 ± 0.11 13.11 ± 0.42 0.245 ± 0.02
F3 27.44 ± 0.30 14.22 ± 0.28 0.272 ± 0.06
F4 28.45 ± 0.33 14.44 ± 0.41 0.225 ± 0.06
F5 29.12 ± 0.21 13.45 ± 0.67 0.245 ± 0.03
F6 28.11 ± 0.36 15.01 ± 0.66 0.224 ± 0.01
F7 26.24 ± 0.11 11.22 ± 0.65 0.210 ± 0.08
F8 29.12 ± 0.51 14.56 ± 0.52 0.299 ± 0.01
F9 28.28 ± 0.32 13.42 ± 0.22 0.257 ± 0.01
F10 28.23 ± 0.26 14.74 ± 0.76 0.260 ± 0.02
*Standard deviation, n = 3
Table 6: Particle size distribution parameters of RNZ 
microparticles
Formulation Volume mean 
diameter 
(D[4,3]) µm
Volume median 
diameter 
(D[v,0.50]) µm
Volume median 
diameter 
(D[v,0.90]) µm
F5 285.76 221.44 599.78
Figure 2: Particle size distribution of formulation F5
Figure 3: FT-IR spectra showing drug-polymer compatibility194   Journal of Young Pharmacists Vol 3 / No 3
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SEM photographs showed that the drug-loaded 
microparticles were spherical in nature (mean size of 
around 285.9 µm), had a smooth surface with inward 
dents and shrinkage due to the collapse of the wall of 
the microparticles. SEM photographs shown in Figure 5 
reveal the absence of drug particles on the surface of the 
microparticles indicating the uniform distribution of the 
drug in the walls of the microparticles.
The sphericity factor was obtained in the range 1.00 to 1.09, 
indicating that the prepared formulations were spherical 
in nature.
Drug content was measured in order to ascertain that 
the drug was uniformly distributed in the formulation. 
One hundred mg of the drug-loaded microparticles were 
taken in a 100 ml volumetric flask containing 7.4 pH 
buffer solution, and were shaken for 45 min and then 
filtered through Whatmann No.1 filter paper. The amount 
of RNZ present in the buffer solution was determined 
spectrophotometrically at 270 nm. The percentage of drug 
loading in the formulations was found to be in the range of 
36.35–45.23. The percentage encapsulation efficiency was 
found to be 65.25–89.66. The results obtained are given in 
Table 7. Formulation F5 showed maximum drug loading 
when compared to other formulations.
In vitro release studies were carried out for all formulations 
in both gastric and intestinal media. For the formulations 
F1–F10, as shown in Figure 6, it was noticed that the drug 
release rate decreases with increase in EC concentration. 
Studies also showed that the drug release rate increases with 
increase in EU RL 100 concentration. The drug release 
profile of optimized RNZ microparticle formulations 
was compared with the marketed formulation of RNZ 
(Ranexa SR) [Figure 7]. Among the prepared formulations 
the F5 formulation showed good controlled release effect 
based on release profile, similarity factor, differential factor, 
model fitting and release kinetics.
From the release studies it was observed that there is 
no significant release of drug in gastric pH from the 
microparticles and this indicates that the used polymer 
blend is gastro-resistant in nature. In intestinal pH, drug  Figure 4: DSC comparison of pure drug and formulation F5
Figure 5: SEM photograph of formulation F5Journal of Young Pharmacists Vol 3 / No 3  195
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was released in a biphasic manner consisting of an initial 
fast release stage followed by a slow release.
Initial drug release from drug-loaded microparticles in the 
intestinal environment was associated with initial burst 
release. The burst release in the intestinal pH might be 
due to the release of surface-accumulated drug. After the 
initial burst effect, the subsequent release of the drug was 
slow and sustained. From the present study, it was observed   
EC (225:75) in a ratio of (225:75) i.e. a increase in EU 
concentration  and a decrease in  EC  concentration helps 
to control the drug release from the particles.
The similarity factor fit the result between 50 and 100. It 
approached 0 as the dissimilarity of the test and the reference 
profile increased, whereas it attained 100 when the test and 
the reference profile were identical. The two profiles were 
believed to be similar when their f1 value was between 0 to 15 
(3.48 for F5) and their f2 value was larger than 50 (82.1 for F5), 
for which the mean deviation over all time points ‘n’ was less 
than 10% based on above equation. Formulation 5 showed 
that it was most similar to the marketed reference standard.
Table 8 lists the composition of the RNZ microparticles, and     
expected and experimented values of all the formulations. 
From the presented results the release in 1h varies in a 
non-linear fashion and with increase in the amount of EU 
or decrease in the amount of EC. From the results it was 
observed that EU had exhibited  a considerable effect on 
the drug release. In contrast, the results of the drug release 
revealed that release in 8 h varies in linear fashion  with 
increased amount of EU and decreased amount of EC. 
Time taken for 50% drug release (t50%) varies in a non-
linear fashion.
The data of the in vitro release studies was fitted into various 
mathematical models to determine the best-fit model. The 
results indicated that the best-fit models were the Peppas 
and Higuchi models. In all the cases the value of intercept, 
A was found to be less than 0.5. This indicates that the 
release of the drug from all the formulations followed the 
Fickian mechanism. The amount of drug released versus 
the square root of time was plotted. The plot should be 
linear if the release of the drug from the delivery system is 
diffusion-controlled. The dissolution graphs were found to 
be linear and the results inferred that the drug release from 
the microparticle formulation was by diffusion.
CONCLUSION
The objective of this study was to prepare and evaluate 
microparticles of an EU and EC mixture loaded with 
RNZ for controlled release by the phase separation 
method. Spherical discrete microparticles were obtained. 
The prepared microparticles exhibited good micromeritic 
properties. From the results of the particle size analysis 
it was clear that all the process variables were within the 
limits and the process is reproducible. FT-IR studies 
indicated that there was no interaction between the 
drug and the polymers in the prepared microparticles. 
Table 7: Drug loading and encapsulation efficiency of 
prepared microparticles
Formulation Drug loading 
(mg) mean ± SD*
Encapsulation efficiency 
(%) mean ± SD*
F1 41.21 ± 0.36 71.10 ±0.26
F2 39.42 ± 0.57 72.32 ± 0.33
F3 41.32 ± 0.56 81.33 ± 1.05
F4 37.50 ± 0.44 73.45 ± 0.33
F5 45.23 ± 0.36 89.66 ± 0.56
F6 40.21 ± 0.26 65.25 ±0.32
F7 36.35 ± 0.33 69.20 ± 0.44
F8 39.72 ± 0.42 76.40 ± 0.66
F9 36.70 ± 0.38 70.70 ± 0.48
F10 41.60 ± 0.44 84.42 ± 0.67
*Standard deviation, n = 3
Figure 6: In vitro drug release profile of prepared RNZ microparticles’ 
formulations. F1(-▲-), F2(-∆-), F3(-■-), F4(-□-), F5(-●-), F6(-○-),   
F7(-♦-), F8(-◊-), F9(-x-), F10(—-)
Figure 7: In vitro drug release profile of prepared RNZ microparticles’ 
formulations. F5 (-♦-), F4 (-□-)196   Journal of Young Pharmacists Vol 3 / No 3
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The DSC thermograms obtained from the pure drug 
and the formulation showed no significant shift in the 
endothermic peaks confirming the stability of the drug in 
the formulation. The in vitro drug release studies showed 
that the release of the drug was found to be diffusion-
controlled. Results of dissolution studies for formulation 
F5 and the marketed product showed that both have 
nearly similar release profiles. From the results, it can be 
concluded that the microparticles’ formulation is easy 
to administer, simple, and economical with increased 
patient compliance. Hence RNZ could be formulated 
into microparticles as a controlled drug release dosage 
form by the phase separation method.
These results demonstrate the potential use of EU and EC 
combinations for fabrication of delivery systems of other 
water soluble drugs in a controlled manner.
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Table 8: Formulations, response, and predicted values 
of RNZ microparticles
Formulation Response variable Observed value Predicted value
F1 1 h (%) 6.51 6.48
12 h (%) 81.2 81.32
t50 h 4.30 4.32
F2 1 h (%) 5.81 5.91
12 h (%) 77.24 77.41
t50 h 4.20 4.16
F3 1 h (%) 7.15 7.24
12 h (%) 82.91 83.01
t50 h 3.50 3.42
F4 1 h (%) 7.67 7.81
12 h (%) 71.33 71.42
t50 h 4 4.01
F5 1 h (%) 7.35 7.35
12 h (%) 87.98 87.98
t50 h 3.40 3.4
F6 1 h (%) 6.81 6.87
12 h (%) 80.5 80.63
t50 h 4.10 4.09
F7 1 h (%) 5.56 5.41
12 h (%) 75.1 75.69
t50 h 4.05 4.52
F8 1 h (%) 7.41 7.36
12 h (%) 81.26 81.34
t50 h 3.50 3.49
F9 1 h (%) 6.21 6.34
12 h (%) 71.5 71.42
t50 h 4.05 4.01
F10 1 h (%) 6.21 6.32
12 h (%) 83.66 83.74
t50 h 3.40 3.46
Announcement
Android App
A free application to browse and search the journal’s content is now available for Android based 
mobiles and devices. The application provides “Table of Contents” of the latest issues, which 
are stored on the device for future offline browsing. Internet connection is required to access the 
back issues and search facility. The application is compatible with all the versions of Android. The 
application can be downloaded from https://market.android.com/details?id=comm.app.medknow. 
For suggestions and comments do write back to us.